Women’s cancer screening and early detection guidance covering cervical, breast, endometrial and ovarian cancer risk.
Screening is testing people who do not have symptoms. A new breast lump, postmenopausal bleeding or persistent pelvic symptoms needs diagnostic assessment rather than waiting for a routine screening date.
The appropriate test and interval depend on age, past results, previous surgery, immune status and family history. India’s public-health programme includes population-based cervical and breast screening for women aged 30–65; private-care pathways may use different validated cervical tests and risk-based breast imaging.
Persistent high-risk HPV causes most cervical cancer. HPV vaccination and screening can prevent many cases by identifying risk or precancer before invasive cancer develops.
Breast awareness helps someone notice a change, while clinical examination and imaging are used according to age and risk. One schedule does not fit every woman.
There is no routine population screening test for average-risk women. Unexpected bleeding—especially after menopause—is the key reason for timely assessment.
Routine ultrasound or CA-125 screening has not been shown to be an effective population screen for average-risk women. Persistent symptoms and inherited risk are managed differently.
No. Programmes may use HPV testing, cervical cytology (Pap testing), co-testing or VIA. The appropriate method and interval depend on the programme, age, risk and previous results.
No. These are not recommended as routine ovarian-cancer screening for average-risk women. They may be used for symptoms, a mass or a specialist high-risk pathway.
It can. Cancer type, which relative was affected and age at diagnosis matter. Some patterns justify genetic counselling, earlier imaging or risk-reducing options.
